Prophylactic and risk-reducing bilateral salpingo-oophorectomy: Recommendations based on risk of ovarian cancer

Obstetrics and Gynecology

Volumn 116, Issue 3, 2010, Pages 733-743

  Berek, Jonathan S ^a   Chalas, Eva ^b   Edelson, Mitchell ^b   Moore, David H ^b   Burke, William M ^b   Cliby, William A ^b   Berchuck, Andrew ^b  

^a STANFORD UNIVERSITY SCHOOL OF MEDICINE   (United States)

^b NONE

Author keywords

[No Author keywords available]

Indexed keywords

BISPHOSPHONIC ACID DERIVATIVE; BRCA1 PROTEIN; BRCA2 PROTEIN; CALCIUM; CLONIDINE; CONJUGATED ESTROGEN; CONTRACEPTIVE AGENT; ESTROGEN; GABAPENTIN; LUBRICATING AGENT; MEDROXYPROGESTERONE ACETATE; ORAL CONTRACEPTIVE AGENT; PAROXETINE; PLACEBO; PREGABALIN; SEROTONIN UPTAKE INHIBITOR; SERTRALINE; TAMOXIFEN; TESTOSTERONE; VENLAFAXINE; VITAMIN D; ZOLEDRONIC ACID;

CANCER RISK; CARDIOVASCULAR DISEASE; FAMILY HISTORY; GENE MUTATION; HIGH RISK PATIENT; HORMONAL CONTRACEPTION; HOT FLUSH; HUMAN; HYSTERECTOMY; INFORMED CONSENT; MENOPAUSE; NEUROLOGIC DISEASE; ORGAN PRESERVATION; OSTEOPOROSIS; OVARY CANCER; OVARY CONSERVATION; PREMENOPAUSE; PRIORITY JOURNAL; PROPHYLAXIS; REOPERATION; REVIEW; RISK BENEFIT ANALYSIS; RISK REDUCTION; SALPINGOOOPHORECTOMY; SLEEP DISORDER; VAGINA ATROPHY; FEMALE; GENETICS; MUTATION; OVARIECTOMY; OVARY TUMOR; RISK FACTOR; TUMOR SUPPRESSOR GENE;

FEMALE; GENES, BRCA1; GENES, BRCA2; GERM-LINE MUTATION; HUMANS; HYSTERECTOMY; OVARIAN NEOPLASMS; OVARIECTOMY; PREMENOPAUSE; REOPERATION; RISK FACTORS;

EID: 77957285812     PISSN: 00297844     EISSN: None     Source Type: Journal    
DOI: 10.1097/AOG.0b013e3181ec5fc1     Document Type: Review

References (74)

1. Cancer facts and figures 2009. Atlanta (GA): American Cancer Society; 2009.
2. Jemal A, Siegel R, Ward E, Hao Y, Xu J, Thun MJ. Cancer statistics, 2009. CA Cancer J Clin 200;59:225-49.
3. Edmondson RJ, Monaghan JM. The epidemiology of ovarian cancer. Int J Gynecol Cancer 2001;11:423-9.
4. Negri E, Franceschi S, Tzonou A, Booth M, La Vecchia C, Parazzini F, et al. Pooled analysis of three European case-control studies ofepithelial ovarian cancer: I. Reproduc-tive factors and risk of epithelial ovarian cancer. Int J Cancer 1991;49:50-6.
5. Franceschi S, La Vecchia C, Booth M, Tzonou A, Negri E, Parazzini F, et al. Pooled analysis of three European case-control studies of epithelial ovarian cancer: II. Age at menarche and menopause. Int J Cancer 1991;49:57-60.
6. Kurman RJ, Shih Ie M. Pathogenesis of ovarian cancer: lessons from morphology and molecular biology and their clinical implications [review]. Int J Gynecol Pathol 2008;27:151-60.
7. Kindelberger DW, Lee Y, Miron A, Hirsch MS, Feltmate C, Medeiros F, et al. Intraepithelial carcinoma of the fimbria and pelvic serous carcinoma: evidence for a causal relationship. Am J Surg Pathol 2007;31:161-9.
8. Callahan MJ, Crum CP, Medeiros F, Kindelberger DW, Elvin JA, Garber JE, et al. Primary fallopian tube malignancies in BRCA-positive women undergoing surgery for ovarian cancer risk reduction. J Clin Oncol. 2007;25:3985-90.
9. Carlson JW, Miron A, Jarboe EA, Parast MM, Hirsch MS, Lee Y, et al. Serous tubal intraepithelial carcinoma: its potential role in primary peritoneal serous carcinoma and serous cancer prevention. J Clin Oncol 2008;26:4160-5.
10. Levanon K, Crum C, Drapkin R. New insights into the pathogenesis of serous ovarian cancer and its clinical impact. J Clin Oncol 2008;26:5284-93.
11. Engeland A, Tretli S, Bjorge T. Height, body mass index, and ovarian cancer: a follow-up of 1.1 million Norwegian women. J Natl Cancer Inst 2003;95:1244-8.
12. Ness RB, Cramer DW, Goodman MT, Kjaer SK, Mallin K, Mosgaard BJ, et al. Infertility, fertility drugs, and ovarian cancer: a pooled analysis of case-control studies. Am J Epidemiol 2002;155:217-24.
13. Sit AS, Modugno F, Weissfeld JL, Berga SL, Ness RB. Hor-mone replacement therapy formulations and risk of epithelial ovarian carcinoma. Gynecol Oncol 2002;86:118-23.
14. Lacey JV Jr, Mink PJ, Lubin JH, Sherman ME, Troisi R, Hartge P, et al. Menopausal hormone replacement therapy and risk of ovarian cancer.JAMA 2002;288:334-41.
15. Mørch LS, Løkkegaard E, Andreasen AH, Krüger- Kjær S, Lidegaard Ø. Hormone therapy and ovarian cancer. JAMA 2009;302:298-305.
16. Rebbeck TR, Kauff ND, Domchek SM. Meta-analysis of risk reduction estimates associated with risk-reducing salpingo-oophorectomy in BRCA1 or BRCA2 mutations carriers. J Natl Cancer Inst 2009;101:80-7.
17. Tutt A, Ashworth A. The relationship between the roles of BRCA genes in DNA repair and cancer predisposition. Trends Molecular Med 2002;8:571-6.
18. Boyd J. Molecular genetics of hereditary ovarian cancer. Oncology 1998;12:399-406.
19. Risch HA, McLaughlin JR, Cole DE, Rosen B, Bradley L, Kwan L, et al. Prevalence and penetrance of germline BRCA1 and BRCA2 mutations in a population series of 649 women with ovarian cancer. Am J Hum Genet 2001;68:700-10.
20. Antoniou A, Pharoah PD, Narod S, Risch HA, Eyfjord JE, Hopper JL, et al. Average risks of breast and ovarian cancer associated with BRCA1 or BRCA2 mutations detected in case series unselected for family history: a combined analysis of 22 studies. Am J Hum Genet 2003;72:1117-30.
21. Kauff ND, Satagopan JM, Robson ME, Scheuer L, Hensley M, Hudis CA, et al. Risk-reducing salpingo-oophorectomy in women with a BRCA1 or BRCA2 mutation. N Engl J Med 2002;346:1609-15.
22. Rebbeck TR, Lynch HT, Neuhausen SL, Narod SA, van't Veer L, Garber JE, et al, for the Prevention and Observation of Surgical End Points Study Group. Prophylactic oophorectomy in carriers of BRCA1 or BRCA2 mutations. N Engl J Med 2002;346:1616-22.
23. Rebbeck TR, Levin AM, Eisen A, Snyder C, Watson P, Cannon-Albright L, et al. Breast cancer risk after bilateral prophylactic oophorectomy in BRCA1 mutation carriers.J Natl Cancer Inst 1999;91:1475-9.
24. Haber D. Prophylactic oophorectomy to reduce the risk of ovarian and breast cancer in carriers of BRCA mutations. N Engl J Med 2002;346:1660-1.
25. Schrag D, Kuntz KM, Garber JE, Weeks JC. Decision analysis: effects of prophylactic mastectomy and oophorectomy on life expectancy among women with BRCA1 and BRCA2 mutations. N Engl J Med 1997;336:1465-71
26. [Erratum in N Engl J Med 1997;337:434].
27. Franceschi S, Parazzini F, Negri E, Booth M, La Vecchia C, Beral V, et al. Pooled analysis of three European case-control studies ofepithelial ovarian cancer: III. Oral contraceptive use. Int J Cancer 1991;49:61-5.
28. Narod SA, Risch H, Moslehi R, Dorum A, Neuhausen S, Olsson H, et al, and the Hereditary Ovarian Cancer Clinical Study Group. Oral contraceptives and the risk of hereditary ovarian cancer. N Engl J Med 1998;339:424-8.
29. Modan B, Hartge P, Hirsh-Yechezkel G, Chetrit A, Lubin F, Beller U, et al. Parity, oral contracep-tives, and the risk of ovarian cancer among carriers and noncarriers of a BRCA1 or BRCA2 mutation. N Engl J Med 2001;345:235-40.
30. Narod SA, Sun P, Ghadirian P, Lynch H, Isaacs C, Garber J, et al. Tubal ligation and risk of ovarian cancer in carriers of BRCA1 or BRCA2 mutations: a case-control study. Lancet 2001;357:1467-70.
31. Partridge E, Kreimer AR, Greenlee RT, Williams C, Xu JL, Church TR, et al. Results from four rounds of ovarian cancer screening in a randomized trial. Obstet Gynecol 2009;113: 775-82.
32. NIH Consensus Development Panel on Ovarian Cancer. Ovarian cancer: screening, treatment and follow-up. JAMA 1995;273:491-7.
33. Bourne TH, Campbell S, Reynolds KM, Whitehead MI, Hampson J, Royston P, et al. Screening for early familial ovarian cancer with transvaginal ultrasonography and colour blood flow imaging. Br Med J. 1993;306:1025-9.
34. Hermsen BB, Olivier RI, Verheijen RH, van Beurden M, de Hullu JA, Massuger LF, et al. No efficacy of annual gynaeco-logical screening in BRCA1/2 mutation carriers: an observa-tional follow-up study. Br J Cancer 2007;96:1335-42.
35. Woodward ER, Sleightholme HV, Considine AM, Williamson S, McHugo JM, Cruger DG Annual surveillance by CA125 and transvaginal ultrasound for ovarian cancer in both high-risk and population risk women is ineffective. Br J Obstet Gynaecol 2007;114:1500-9.
36. Hogg R, Friedlander M. Biology of epithelial ovarian cancer: implications for screening women at high genetic risk. J Clin Oncol 2004;22:1315-27.
37. Greene MH, Piedmonte M, Alberts D, Gail M, Hensley M, Miner Z, et al. Prospective study of risk-reducing salpingo-oophorectomy and longitudinal CA-125 screening among women at increased genetic risk of ovarian cancer: design and baseline characteristics: a Gynecologic Oncology Group study. Cancer Epidemiol Biomarkers Prev 2008;17:594-604.
38. Parker W, Broder M, Liu Z, Shoupe D, Farquhar C, Berek JS. Ovarian conservation at the time of hysterectomy for benign disease. Obstet Gynecol 2005;106:219-26.
39. Rebbeck TR, Friebel T, Wagner T, Lynch HT, Garber JE, Daly MB, et al. Effect of short-term hormone replacement therapy on breast cancer reduction after bilateral prophylactic oophorectomy in BRCA1 and BRCA2 mutation carriers: the PROSE study group. J Clin Oncol 2005;23:7804-10.
40. Kelsey JL, Bernstein L. Epidemiology and prevention of breast cancer. Annu Rev Public Health 1996;17:47-67.
41. ACOG Practice Bulletin. Compendium of Selected Publica-tions. Prophylactic oophorectomy (original pub 1999). Wash-ington DC: American College of Obstetricians and Gynecol-ogists; 2007. p. 890-5.
42. Levine DA, Lin O, Barakat RR, Robson ME, McDermott D, Cohen L, et al. Risk of endometrial carcinoma associated with BRCA mutation. Gynecol Oncol 2001;80:395-8.
43. Lavie O, Hornreich G, Ben-Arie A. BRCA germline mutations in Jewish women with uterine papillary carcinoma. Gynecol Oncol 2004;92:521-4.
44. Cohen I. Endometrial pathologies associated with postmeno-pausal tamoxifen treatment. Gynecol Oncol 2004;94:256-66.
45. Jacoby VL, Grady D, Sawaya GF. Oophorectomy as a risk for coronary heart disease. Am J Obstet Gynecol 2009;200: 140.e1-9.
46. Mack WJ, Slater CC, Xiang M, Shoupe D, Lobo RA, Hodis HN. Elevated subclinical atherosclerosis associated with oophorectomy is related to time since menopause rather than type of menopause. Fertil Steril 2004;82:391-7.
47. Colditz GA, Willett WC, Stampfer MJ, Rosner B, Speizer FE, Hennekens CH. Menopause and the risk of coronary heart disease in women. N Engl J Med 1987;316:1105-10.
48. Howard BV, Kuller L, Langer R, Manson JE, Allen C, Assaf A, et al, and the Women's Health Initiative. Risk of cardiovascu-lar disease by hysterectomy status, with and without oopho-rectomy: the Women's Health Initiative Observational Study. Circulation 2005;111:1462-70.
49. Rocca WA, Shuster LT, Grossardt BR, Maragnanore DM, Gostout BS, Geda YE, Melton LJ III. Long-term effects of bilateral oophorectomy on brain aging: unanswered questions from the Mayo Clinic Cohort Study of Oophorectomy and Aging. Women's Health (London Engl) 2009;5:39-48.
50. Rocca WA, Grossardt BR, de Andrade M, Malkasian GD, Melton LJ III. Survival patterns after oophorectomy in pre-menopausal women: a population-based cohort study. Lancet Oncol 2006;7:821-8.
51. Rocca WA, Bower JH, Maraganore DM, Ahlskog JE, Grossardt BR, de Andrade M, Melton LJ III. Increased risk of parkinsonism in women who underwent oophorectomy before menopause. Neurology 2008;70:200-9.
52. Rocca WA, Bower JH, Maraganore DM, et al. Increased risk of cognitive impairment or dementia in women who underwent oophorectomy before menopause. Neurology Published online before print August 29, 2007, doi:10.1212/01.wnl. 0000276984.19542.e6. (Pubitemid 47517552)
53. Allison MA, Manson JE, Langer RD, Carr JJ, Rossouw JE, Pettinger MB, et al, and the Women's Health Initiative and Women's Health Initiative Coronary Artery Calcium Study Investigators. Oophorectomy, hormone therapy, and subclin-ical coronary artery disease in women with hysterectomy: the Women's Health Initiative coronary artery calcium study. Menopause 2008;15(4 Pt 1):639-47.
54. Rivera CM, Grossardt BR, Rhodes DJ, Borwn RD Jr, Roger VL, Melton LJ III, Rocca WA. Increased cardiovascular mortality after early bilateral oophorectomy. Menopause 2009; 16:15-23.
55. Parker WH, Broder MS, Chang E, Feskanich D, Farquhar C, Liu Z, et al. Ovarian conservation at the time of hysterectomy and long-term health outcomes in the Nurses' Health Study. Obstet Gynecol 2009;113:1027-37.
56. Plockinger B, Kolbl H. Development of ovarian pathology after hysterectomy without oophorectomy. J Am Coll Surg 1994;178:581-5.
57. Holub Z, Jandourek M, Jabor A, Kliment L, Wágnerová M. Does hysterectomy without salpingo-oophorectomy influence the reoperation rate for adnexal pathology? A retrospective study. Clin Exp Obstet Gynecol 2000;27:109-12.
58. Christ JE, Lotze EC The residual ovary syndrome. Obstet Gynecol 1975;46:551-6.
59. Zalel Y, Lurie S, Beyth Y, Goldberger S, Tepper R. Is it necessary to perform a prophylactic oophorectomy during hysterectomy? Eur J Obstet Gynecol Reprod Biol 1997;73: 67-70.
60. Dekel A, Ewfrat Z, Orvieto R, Levy T, Dicker D, Gal R, et al. The residual ovary syndrome: a 20-year experience. Eur J Obstet Gynecol Reprod Biol 1996;68:159-64.
61. Namnoum AB, Hickman TN, Goodman SB, Gehlbach DL, Rock JA. Incidence of symptom recurrence after hysterectomy for endometriosis. Fertil Steril 1995;64:898-902.
62. Vercellini P, Barbara G, Abbiati A, Somigliana E, Viganò P, Fedele L. Repetitive surgery for recurrent symptomatic endo-metriosis: What to do? Eur J Obstet Gynecol Reprod Biol 2009;146:15-21.
63. Shuster LT, Rhodes DJ, Gostout BS, Grossardt BR, Rocca WA. Premature menopause or early menopause: long-term health consequences. Maruritas 2010;65:161-6.
64. Kotsopoulos J, Lubinski J, Neuhausen SL, Lynch HT, Rosen B, Ainsworth P, et al. Hormone replacement therapy and the risk of ovarian cancer in BRCA1 and BRCA2 mutation carriers. Gynecol Oncol 2006;100:83-8.
65. Rossouw JE, Prentice RL, Manson JE, Wu L, Barad D, Barnabei VM, et al. Postmenopausal hormone therapy and risk of cardiovascular disease by age and years since menopuase.JAMA 2007:1465-77.
66. Rennert G, Rennert HS, Pinchev M, Lavie O, Gruber SB. Use of hormone replacement therapy and the risk of colorectal cancer. J Clin Oncol 2009;27:4542-7.
67. Guidozzi F, Daponte A. Estrogen replacement therapy for ovarian cancer survivors. Cancer 1999;86:1013-8.
68. Barakat RR, Bundy BN, Spirtos NM, Bell J, Mannel RS. Randomized double-blind trial of estrogen replacement ther-apy versus placebo in stage I or II endometrial cancer: a Gynecologic Oncology Group study. J Clin Oncol 2006;24: 587-92.
69. Holmberg L, Anderson H. HABITS (hormonal replacement therapy after breast cancer\is it safe?), a randomised compar-ison: trial stopped. Lancet 2004;363:453-5.
70. Barton DL, Wender DB, Sloan JA, Dalton RJ, Balcueva EP, Athrton PJ, et al. Randomized controlled trial to evaluate transdermal testosterone in female cancer survivors with decreased libido: North Central Cancer Treatment Group Protocol NO2C3. J Natl Cancer Inst 2007;99:672-9.
71. Loprinzi Cl, Pisansky TM, Fonseca R, Sloan JA, Zahasky KM, SK Quella SK, et al. Pilot evaluation of venlafaxine hydrochlo-ride for the therapy of hot flashes in cancer survivors. J Clin Oncol 1998;16:2377-81.
72. Loprinzi CL, Qin R, Baclueva EP, Flynn KA, Rowland KM Jr, Graham DL, et al. Phase III, randomized, double-blind, pla-cebo-controlled evaluation of pregabalin for alleviating hot flashes, N07C1. J Clin Oncol 2010;28:641-7.
73. Gnant MFX, Mlineritsch B, Luschin-Ebengreuth G, Grampp S, Kaessmann H, Schmid M, et al. Zoledronic acid prevents cancer treatment-induced bone loss in premeno-pausal women receiving adjuvant endocrine therapy for hormone-responsive breast cancer: a report from the Austrian Breast and Colorectal Cancer Study Group. J Clin Oncol 2007;25:820-8.
74. Lancaster JM, Powell CB, Kauff ND, Cass I, Chen LM, Lu KH, Mutch DG, Berchuck A, Karlan BY, Herzog TJ; Society of Gynecologic Oncologists Education Committee. Gynecol Oncol 2007;107:159-62.